The Lonza Board of Directors has announced the nomination of Stephen Fry as an Independent Member of the Board, subject to election at the company's Annual General Meeting in May 2026. If elected, Fry will also join the People and Governance Committee and the Audit and Compliance Committee, bringing extensive pharmaceutical industry experience and a global leadership perspective.
Fry spent over three decades at Eli Lilly and Company, where he held a variety of international, operational, and executive leadership roles. He served as Executive Vice President and Chief Human Resources Officer for 12 years, leading large-scale organizational transformation and shaping high-performance cultures. His expertise in succession planning, people strategy development, and organizational governance is expected to complement the existing board capabilities.
Jean-Marc Huet, Chairman of the Lonza Board, commented: 'Stephen brings extensive international experience, combined with a strong track record in organizational governance, succession planning and people strategy development, all of which form a valuable complementary fit with the capabilities of our other Board members. Stephen will play an important role in helping develop and embed our performance culture. This will support our ambition to attract and retain world-leading talent and bring our high-performing teams to the next level.'
Lonza, the world's largest contract development and manufacturing organization (CDMO), serves the healthcare industry with a team of approximately 20,000 colleagues across five continents. The company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. More information is available at www.lonza.com.
Fry's appointment is part of Lonza's ongoing efforts to strengthen its board with leaders who have deep industry knowledge and a proven ability to drive organizational change. The nomination underscores Lonza's commitment to enhancing its performance culture and governance framework as it continues to support pharma and biotech companies in bringing life-saving treatments to patients worldwide.
